Demonstratives
Defense Exhibit 10685
Contains calculations from customer-receipt and option or stock-proceeds rows in Exhibit 5172. It was also described in closing argument as a Theranos record reflecting more than $200 million in deferred revenue.
Exhibit 10685Option/stock proceeds summaryTheranos record reflecting more than $200 million in deferred revenue
MentionedFederal Criminal Trial